深圳迈瑞生物医疗电子股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届董事会第三次会议于 2023年8月28日上午11:00在香港文华东方酒店会议室以现场结合通讯方式召开，会议通知于 2023年8月18日以电子邮件等方式送达全体董事。 会议由公司董事长李西廷先生主持。本次会议应出席董事人数11人，实际出席董事人 数11人，其中董事吴昊先生以通讯表决方式参会，董事成明和先生因个人原因未能亲自出 席会议，授权委托董事李西廷先生代为出席并行使表决权。本次会议的召集、召开符合《中 华人民共和国公司法》和《深圳迈瑞生物医疗电子股份有限公司章程》等有关规定。 二、董事会会议审议情况 证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-048 公司全体独立董事对本议案发表了同意的独立意见。 具体内容详见公司同日刊载于巨潮资讯网（www.cninfo.com.cn）上的相关公告。 表决结果：同意票11票、反对票0票、弃权票0票。 2、审议通 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关规定，现将 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）2023年半年度募集资金存放与实 际使用情况报告如下： 证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-050 深圳迈瑞生物医疗电子股份有限公司 2023年半年度募集资金存放与实际使用情况的专项报告 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"证监会"）签发的《关于核准深圳迈瑞生物 医疗电子股份有限公司首次公开发行股票的批复》（证监许可[2018] 1436号文），公司于2018 年10月向社会公众发行人民币普通股121,600,000股，每股发行价格为人民币48.80元，募集 资金总额为人民币5,934,080,000.00元。扣除承销保荐费用人民币138,396,226.41元，实际收 到募集资金人民币5,795,683,773.59元。扣除发行中介费用人民币43,88 ...

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 证券代码：300760 证券简称：迈瑞医疗 编号：2023-005 投资者关系活动记录表 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 ☑路演活动 活动类别 ☑现场参观 ☑其他 电话会议、券商策略会 参与单位名 169 家机构 265 名参与人员，详见附件清单。 称及人员姓 名 时间 2023 年 7 月 3-7 日、7 月 10-14 日、7 月 17 日、7 月 19-21 日、7 月 24-28 日、7 月 31 日 深圳市南山区高新技术产业园区科技南十二路迈瑞大厦 洛杉矶、纽约、波士顿、上海投资人办公室 地点 券商策略会会场 董事会秘书李文楣 上市公司接 投资者关系团队钱宇浩、杨惠茹 待人员姓名 1、互动提问 问：公司近日公告拟收购境外标的 DiaSys Diagnostic 75%的股权，请 问这笔并购对公司的意义是什么？为什么选择收购 DiaSys Diagnostic？ 答：体外诊断是支撑公司未来长远发展的核心业务之一，而实现体外诊 投资者关系 断全面国际化更是其中不得不迈出的关键一步。但一直以来，海外供 ...

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 证券代码：300760 证券简称：迈瑞医疗 编号：2023-004 深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 ☑特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 投资者关系 □新闻发布会 ☑路演活动 活动类别 ☑现场参观 □其他 电话会议、券商策略会、股东大会 参与单位名 515 家机构 862 名参与人员，详见附件清单。 称及人员姓 名 时间 2023 年 5 月 4-6 日、5 月 8-12 日、5 月 15-19 日、5 月 22-26 日、5 月 31 日、6 月 1-2 日、6 月 5-6 日、6 月 8 日、6 月 12-14 日、6 月 16 日、6 月 19-22 日、6 月 26-30 日 深圳市南山区高新技术产业园区科技南十二路迈瑞大厦 深圳四季酒店 上海裕景大饭店 上海柏悦酒店 上海金茂君悦大酒店 上海浦东嘉里大酒店 地点 上海文华东方酒店 上海东方滨江大酒店 上海静安香格里拉大酒店 上海浦东香格里拉大酒店 上海国际会议中心 北京金融街威斯汀大酒店 深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 苏州洲际酒 ...

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 证券代码：300760 证券简称：迈瑞医疗 编号：2023-003 深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 ☐媒体采访 业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他 参与单位名称 及人员姓名 线上参与公司 2022 年度网上业绩说明会的全体投资者 时间 2023 年 05 月 06 日 15:00-17:00 地点 价值在线（https://www.ir-online.cn/） 董事长 李西廷 总经理、董事 吴昊 上市公司接待 财务负责人 赵云 人员姓名 董事会秘书 李文楣 独立董事 吴祈耀 1、互动提问 问：公司所处行业未来发展趋势如何？迈瑞医疗在行业中的地位怎 样？有什么核心竞争力？ 答：中国和中国以外发展中国家医疗器械市场增长迅速，全球医疗器 投资者关系活 械市场持续稳定增长。我国是人口大国，人口老龄化程度不断提高。随着 动主要内容介 经济的快速发展，民众支付能力不断增强，医疗体系逐步完善，我国医疗 绍 器械行业增长迅速，已经成为全球第二大市场。 从国内市场来看，公司产 ...

R&D Investment and Innovation - Mindray invested over 11 billion RMB in R&D over the past 5 years, resulting in more than a doubling of revenue[3] - The company is investing CNY 1 billion in R&D for new product development, focusing on advanced imaging and minimally invasive surgical technologies[16] - The company plans to invest 1 billion RMB in research and development over the next three years to enhance its product innovation capabilities[19] - The company’s R&D investment reached CNY 3,190.973 million, a year-on-year increase of 17.06%[66] - The company has filed a total of 8,670 patent applications, including 6,193 invention patents, with 3,976 patents granted[66] - The company has maintained a consistent R&D investment strategy, with R&D expenses as a percentage of operating revenue remaining above 10% for the past three years[158] - The company is actively pursuing innovation in medical devices, with several products classified as innovative medical devices under registration[162] - The company is focused on innovation, as evidenced by the introduction of advanced features in its new products, such as real-time imaging capabilities in endoscopic systems[181] Market Expansion and Revenue Growth - International business revenue exceeded 11 billion RMB in 2022, with a strong presence established in North America, Europe, Asia, Africa, and Latin America[7] - Mindray plans to expand its market presence in Southeast Asia, targeting a 30% growth in this region over the next three years[17] - The company has set a revenue guidance of CNY 22 billion for 2023, representing a growth target of 10%[16] - The company expects a revenue growth forecast of 12% to 15% for 2023, driven by new product launches and market expansion strategies[19] - The company achieved a significant increase in revenue, achieving a total of 10 billion RMB in 2022, representing a year-over-year growth of 15%[19] - The company reported a revenue increase of 15% year-over-year, reaching approximately CNY 20 billion in 2022[16] - The company’s international revenue in 2022 was around RMB 11.7 billion, with a market share in the low single digits, indicating significant growth potential in international markets[120] Product Development and Launches - Mindray aims to launch three new product lines in 2023, including next-generation ultrasound systems and innovative diagnostic solutions[17] - A total of 30 new products are expected to be launched in 2023, including advanced imaging and diagnostic equipment[20] - The company launched several new products in the medical imaging field, including the high-end Resona R9 Platinum and Nuewa R9 Platinum ultrasound machines, and various POC ultrasound solutions[77] - The company introduced new products in the life information and support sector, enhancing its portfolio with solutions like the SV70 non-invasive ventilator and the BeneHeart D series defibrillator[74] - The company has launched several new products, including the adult non-invasive ventilator and the new platform surgical bed, enhancing its competitive position in the respiratory solutions market[150] - The company has introduced advanced devices such as the anesthesia machine and the automatic coagulation analyzer, both classified as Class III, enhancing its product portfolio for critical care[181] Financial Performance - The company achieved a net profit margin of 18%, reflecting strong operational efficiency and cost management strategies[17] - The company's operating revenue for 2022 was ¥30,365,643,811, representing a 20.17% increase from ¥25,269,580,818 in 2021[25] - The net profit attributable to shareholders for 2022 was ¥9,607,174,094, up 20.07% from ¥8,001,553,606 in 2021[25] - The basic earnings per share for 2022 was ¥7.9402, reflecting a 20.55% increase from ¥6.5868 in 2021[26] - The company reported a diluted earnings per share of ¥7.9369 for 2022, up 20.50% from ¥6.5868 in 2021[26] - The total profit reached CNY 1,095,355.07 million, reflecting a growth of 21.48% compared to the previous year[71] Strategic Partnerships and Acquisitions - Mindray is exploring strategic acquisitions to enhance its product portfolio and market reach, particularly in the IVD sector[17] - The company has established partnerships with several universities and hospitals to develop core technologies, including the array probe and multispectral photoacoustic imaging technology, breaking the import monopoly in the cardiac ultrasound field[91] - The company has signed cooperation agreements with 9 IDN medical alliances in North America, with one exclusive supply agreement for monitoring equipment contributing over $20 million in revenue during the reporting period, expected to generate nearly $100 million in sales over the contract duration[101] Regulatory Compliance and Quality Management - The company’s quality management system passed 90 audits during the reporting period, maintaining high standards for product quality[129] - The company has received multiple product registrations during the reporting period, including a digital X-ray imaging system classified as Class II, valid until June 2029[188] - The company is committed to maintaining high standards of quality and compliance in its product offerings, ensuring that all new products meet regulatory requirements[182] Sustainability and Social Responsibility - Mindray's commitment to sustainability includes initiatives to reduce carbon emissions by 15% over the next five years[17] - The company emphasizes the importance of rational investment and risk awareness in its forward-looking statements regarding future development plans[9] - The report includes a detailed discussion of potential risk factors and corresponding countermeasures that the company may face in the future[9] Market Trends and Industry Outlook - The global medical device market exceeds 500 billion USD, with Mindray's corresponding market space at approximately 550 billion RMB, indicating significant growth potential[7] - The healthcare sector is entering a new expansion cycle, with increasing demand for medical devices as hospitals complete construction projects[36] - The medical device industry in China is expected to gradually recover and achieve steady growth in exports, particularly in high-tech and high-value-added products, as companies enhance their resilience and innovation capabilities[58]

Financial Performance - The company's revenue for Q1 2023 reached ¥8,364,281,841, representing a 20.47% increase compared to ¥6,943,108,994 in the same period last year[3]. - Net profit attributable to shareholders was ¥2,571,117,273, up 22.14% from ¥2,105,071,901 year-over-year[3]. - Basic earnings per share rose to ¥2.1260, reflecting a 22.36% increase from ¥1.7375 in the previous year[3]. - Total operating revenue for Q1 2023 reached ¥8,364,281,841, a 20.4% increase from ¥6,943,108,994 in the same period last year[17]. - Net profit for Q1 2023 was ¥2,572,339,003, representing a 22.1% increase compared to ¥2,106,972,682 in Q1 2022[18]. - Operating profit for the current period was ¥2,899,684,588, up from ¥2,401,535,649, marking a 20.8% increase year-over-year[18]. - Total comprehensive income for Q1 2023 was ¥2,577,475,440, up from ¥2,025,451,984, reflecting a growth of 27.3%[19]. - Total operating costs for the current period were ¥5,572,679,803, which is a 20.4% increase from ¥4,630,030,820 in the same period last year[17]. Cash Flow and Assets - The net cash flow from operating activities increased by 53.30%, amounting to ¥1,333,357,505, primarily due to higher cash receipts from sales of goods and services[6]. - Cash flow from operating activities amounted to ¥1,333,357,505, compared to ¥869,750,366 in the same quarter last year, indicating a 53.3% increase[20]. - The company's cash and cash equivalents amounted to CNY 23.91 billion, up from CNY 23.19 billion, indicating a growth of about 3.1%[14]. - The total assets at the end of the reporting period were ¥48,558,714,507, a 3.88% increase from ¥46,745,236,809 at the end of the previous year[3]. - The total liabilities decreased to CNY 13.89 billion from CNY 14.75 billion, a reduction of about 5.8%[16]. - The equity attributable to shareholders rose to CNY 34.65 billion from CNY 31.98 billion, showing an increase of approximately 8.3%[16]. Research and Development - R&D investment in Q1 2023 was CNY 938 million, accounting for 11.21% of operating revenue, with a year-on-year increase of 26.30%[11]. - Research and development expenses increased to ¥852,300,844, a rise of 21.1% from ¥703,945,494 in the previous year[17]. - As of March 31, 2023, the company had applied for a total of 8,892 patents, including 6,357 invention patents, with 4,187 patents granted[11]. - The company launched new products in Q1 2023, including the AF-600 fully automated microbial identification and susceptibility analysis instrument and the HyLED C series surgical lights[11]. Market and Strategic Initiatives - The company plans to enhance product competitiveness and market penetration by focusing on high-end hospitals and large third-party laboratory chains[10]. - The domestic ICU market saw a significant increase in demand for critical care equipment, leading to a shift in production capacity towards these products[10]. - The company expects a rebound in the performance of in vitro diagnostics and medical imaging businesses, as well as overseas markets in the upcoming months[10]. - The establishment of the Zhuhai-Macao Remote Ultrasound Alliance aims to improve medical services in the Greater Bay Area and Guizhou Province[12]. - The company is committed to enhancing basic medical infrastructure and talent training to provide better healthcare services to a wider population[12]. Shareholder Information - The company reported a total of 63,099 common shareholders at the end of the reporting period[7]. - Smartco Development Limited and Magnifice (HK) Limited were the top two shareholders, holding 26.98% and 24.49% of shares, respectively[7]. Social Responsibility - The company donated medical equipment worth USD 200,000 to Turkey for earthquake relief efforts, demonstrating its commitment to social responsibility[13]. - In Q1 2023, Mindray's AED devices successfully treated 20 patients in China, contributing to a total of 168 lives saved since inception[13]. - The company plans to complete the new campus of Dazhang Middle School by June 2025, which will significantly enhance the educational capacity[13]. Other Financial Information - The company received government subsidies amounting to ¥61,723,021 during the reporting period[5]. - Other income for the current period was ¥199,644,189, an increase from ¥113,998,291 in the same period last year[17]. - Cash outflow from investment activities totaled $535,236,403, an increase from $381,172,038 in the previous period, resulting in a net cash flow from investment activities of -$497,127,763 compared to -$294,278,032[21]. - Cash outflow from financing activities was $37,237,728, significantly lower than $1,023,069,387 in the previous period, leading to a net cash flow from financing activities of -$37,237,728 compared to -$1,023,069,387[21]. - The impact of exchange rate changes on cash and cash equivalents was -$69,123,212, compared to -$15,757,666 in the previous period[21]. - The net increase in cash and cash equivalents was $729,868,802, a turnaround from a decrease of -$463,354,719 in the previous period[21]. - The beginning balance of cash and cash equivalents was $18,973,643,833, up from $15,132,728,506 in the previous period[21]. - The ending balance of cash and cash equivalents reached $19,703,512,635, compared to $14,669,373,787 in the previous period[21]. - The company’s first quarter report for 2023 was not audited[22].

证券代码：300760 证券简称：迈瑞医疗 公告编号：2023-022 深圳迈瑞生物医疗电子股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）已于2023年4月28日在巨潮 资讯网上披露了《2022年年度报告》及《2022年年度报告摘要》。为便于广大投资者更加全 面深入地了解公司经营业绩、发展战略等情况，公司定于2023年5月6日（星期六）15:00-17:00 在"价值在线"（www.ir-online.cn）举办深圳迈瑞生物医疗电子股份有限公司2022年度网上 业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 会议召开方式：网络互动方式 二、参加人员 董事长李西廷，董事兼总经理吴昊，财务负责人赵云，董事会秘书李文楣，独立董事 会议召开时间：2023 年 5 月 6 日（星期六）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2023 ...